Bristol Myers Squibb stock at USD 62.86 on September 25, 2026
Published on 09/28/2026 at 08:08 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock last traded at USD 62.86 on September 25, 2026, up 2.22 percent from the previous session. The quote is for Bristol Myers Squibb’s primary NYSE-listed shares.
Clinical results reported
On September 25, Bristol Myers Squibb reported first-time presentation of results from the prespecified analysis of its Phase 3 EXCALIBER-RRMM trial evaluating ZENBEXUS (iberdomide) with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma. The company said the trial’s MRD-negative complete-response rate was 41.10 percent with the ZENBEXUS combination versus 20.70 percent with daratumumab, bortezomib and dexamethasone, based on 420 evaluable patients at a median follow-up of 15.7 months. Bristol Myers Squibb said the results were presented at the International Myeloma Society’s 2026 meeting and simultaneously published in The Lancet Oncology.
Next scheduled results
Bristol Myers Squibb’s investor-relations calendar lists October 29, 2026, for the company’s third-quarter 2026 results and an 8:00 a.m. ET conference call. Bristol Myers Squibb’s investor-relations site also lists the company’s September 18 announcement of that reporting date.
